Cost-effectiveness of catheter-based radiofrequency renal denervation for the treatment of uncontrolled hypertension: an analysis for the UK based on recent clinical evidence
2024

Cost-effectiveness of Catheter-based Radiofrequency Renal Denervation for Uncontrolled Hypertension

Sample size: 337 publication 10 minutes Evidence: high

Author Information

Author(s): Sharp Andrew S P, Cao Khoa N, Esler Murray D, Kandzari David E, Lobo Melvin D, Schmieder Roland E, Pietzsch Jan B

Primary Institution: University Hospital of Wales and Cardiff University

Hypothesis

Is catheter-based radiofrequency renal denervation a cost-effective treatment for uncontrolled hypertension in the UK?

Conclusion

Catheter-based radiofrequency renal denervation can be a cost-effective strategy for uncontrolled hypertension in the UK.

Supporting Evidence

  • RF RDN resulted in a relative risk reduction in clinical events over 10 years.
  • The incremental cost-effectiveness ratio (ICER) was evaluated against the NICE cost-effectiveness threshold.
  • Findings were robust across tested scenarios.
  • RF RDN added 0.35 QALYs at a cost of £4763.

Takeaway

This study shows that a new treatment for high blood pressure can save money and help people live longer and healthier lives.

Methodology

A decision-analytic model was used to project clinical events, quality-adjusted life years (QALYs), and costs based on multivariate risk equations.

Potential Biases

Potential variability in treatment effect among different demographics and comorbidities.

Limitations

The model does not capture repeat clinical events or a broader range of cardiovascular sequelae.

Participant Demographics

Participants were, on average, 55 years old with a baseline office systolic blood pressure of 163 mmHg.

Statistical Information

P-Value

4.9 mmHg

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1093/ehjqcco/qcae001

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication